Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on September 22, 2003

Circulation. 2003
Published online before print September 22, 2003, doi: 10.1161/01.CIR.0000089375.60050.35
A more recent version of this article appeared on October 7, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/14/1735    most recent
01.CIR.0000089375.60050.35v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Navab, M.
Right arrow Articles by Fogelman, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navab, M.
Right arrow Articles by Fogelman, A. M.
Related Collections
Right arrow Pathophysiology
Right arrow Lipid and lipoprotein metabolism
Right arrow Mechanism of atherosclerosis/growth factors

Submitted on October 23, 2002
Revised on June 13, 2003
Accepted on June 18, 2003

Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E-Null Mice

Mohamad Navab PhD*, Susan Hama BSc, Greg Hough MS, and Alan M. Fogelman MD

From the Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, Calif.

* To whom correspondence should be addressed. E-mail: mnavab{at}mednet.ucla.edu.

Background--Lecithin has been widely sold as a dietary supplement. 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) is a phospholipid that does not exist in nature and has been used in vitro to study lipid binding. We tested DMPC in vivo in apolipoprotein (apo) E-null mice.

Methods and Results--DMPC or soy or egg lecithin at 1.0 mg/mL was added to the drinking water of 4-week-old apoE-null female mice. Eight weeks later, HDL cholesterol levels and apoA-I levels were markedly increased in the mice that received DMPC. HDL function was also dramatically improved in the mice receiving DMPC, and there was a significant reduction in aortic lesions (P=0.021) in the DMPC mice but not in those receiving lecithin. Adding 1.0 mg/mL of DMPC to the drinking water of 10-month-old apoE-null female mice for 5 weeks caused regression of aortic sinus lesions (P=0.003). Adding 1.0 mg/mL DMPC to the drinking water of 6-month-old apoE-null male mice for 8 weeks significantly reduced aortic sinus lesion area (P=0.0031) and en face whole aorta lesion area (P=0.001), whereas adding the same concentrations of soy or egg lecithin did not significantly alter lesion area. Jejunal apoA-I synthesis and plasma apoA-I levels were increased 2- to 3-fold in mice receiving DMPC but not soy or egg lecithin.

Conclusions--DMPC (but not lecithin) raises HDL cholesterol and apoA-I, improves HDL function, and prevents lesions or causes their regression in apoE-null mice.


Key words: atherosclerosis • lipids • lipoproteins




This article has been cited by other articles:


Home page
JAMAHome page
I. M. Singh, M. H. Shishehbor, and B. J. Ansell
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
JAMA, August 15, 2007; 298(7): 786 - 798.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M McMahon, J Grossman, W Chen, and B H Hahn
Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus
Lupus, November 1, 2006; 15(11_suppl): 59 - 69.
[Abstract] [PDF]


Home page
CirculationHome page
D. Duffy and D. J. Rader
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Circulation, February 28, 2006; 113(8): 1140 - 1150.
[Full Text] [PDF]


Home page
Circ. Res.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, J. S. Frank, V. R. Grijalva, V. K. Ganesh, V. K. Mishra, M. N. Palgunachari, et al.
Oral Small Peptides Render HDL Antiinflammatory in Mice and Monkeys and Reduce Atherosclerosis in ApoE Null Mice
Circ. Res., September 16, 2005; 97(6): 524 - 532.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, A. C. Wagner, S. Hama, G. Hough, E. Bachini, D. W. Garber, V. K. Mishra, et al.
An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein E-Null Mice
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1932 - 1937.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, G.M. Anantharamaiah, S. Hama, G. Hough, S. T. Reddy, J. S. Frank, D. W. Garber, S. Handattu, and A. M. Fogelman
D-4F and Statins Synergize to Render HDL Antiinflammatory in Mice and Monkeys and Cause Lesion Regression in Old Apolipoprotein E-Null Mice
Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1426 - 1432.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. S. Forrester, R. Makkar, and P.K. Shah
Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians
Circulation, April 12, 2005; 111(14): 1847 - 1854.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. T. Reddy, J. T. Nguyen, V. Grijalva, G. Hough, S. Hama, M. Navab, and A. M. Fogelman
Potential Role for Mitogen-Activated Protein Kinase Phosphatase-1 in the Development of Atherosclerotic Lesions in Mouse Models
Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1676 - 1681.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. Olchawa, B. A. Kingwell, A. Hoang, L. Schneider, O. Miyazaki, P. Nestel, and D. Sviridov
Physical Fitness and Reverse Cholesterol Transport
Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1087 - 1091.
[Abstract] [Full Text] [PDF]